Used in targeted cancer therapies, particularly for solid tumors expressing GPR49/LGR5, such as colorectal, gastric, and hepatocellular carcinomas. Binds specifically to LGR5, a marker of cancer stem cells, enabling selective targeting to inhibit tumor growth and recurrence. Employed in antibody-drug conjugates (ADCs) and bispecific antibody formats to deliver cytotoxic agents directly to tumor cells. Also utilized in diagnostic imaging to detect LGR5-positive tumors and monitor treatment response. Supports regenerative medicine research by identifying and isolating stem cell populations in tissues.